-
Jan 13, 2025 | 
oncnursingnews.com | Chris Ryan
Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC), as demonstrated by improved event-free survival in the phase 3 CREST trial (NCT04165317).1Regarding safety, the toxicity profile of sasanlimab plus BCG was consistent with the known safety data for BCG and previously reported clinical trial findings for sasanlimab.
-
Dec 5, 2024 | 
oncnursingnews.com | Chris Ryan
Toripalimab-tpzi (Loqtorzi) in combination with cisplatin and gemcitabine was listed as the lone preferred first-line treatment regimen for patients with recurrent, unresectable, oligometastatic, or metastatic nasopharyngeal carcinoma (NPC) where surgery and radiotherapy are not options in the updated 2025 version of the National Comprehensive Cancer Network (NCCN) Guidelines for head and neck cancers.1 Additionally, toripalimab monotherapy is listed as the lone preferred option in subsequent...
-
Dec 3, 2024 | 
dialnet.unirioja.es | Chris Ryan
Ayuda Buscar en la ayuda Buscar en la ayuda The Fuxi Taihao Mausoleum: sustaining cultural tradition Zhang, Xiaoyu Nancy [1] ; Chris Ryan [2] ; Zhang, Guangyi Johnny [1] ; Wan, Yanyan Daisy [1] [1] Beijing Union University, Beijing, China [2] University of Waikato, Hamilton,New Zealand Localización: Tourism recreation research, ISSN 0250-8281, Vol. 49, Nº.
-
Dec 1, 2024 | 
oncnursingnews.com | Chris Ryan
The FDA has accepted a biologics license application (BLA) seeking the approval of belantamab mafodotin (Blenrep)–based combinations.
-
Nov 26, 2024 | 
oncnursingnews.com | Chris Ryan
The FDA approved an oral solution of imatinib (Imkeldi) for the treatment of multiple cancer types.1Imatinib (Gleevec) was initially approved by the FDA in 2001 and is indicated for use across a wide array of hematologic and solid tumor malignancies.
-
Nov 22, 2024 | 
oncnursingnews.com | Chris Ryan
The FDA accepted a supplemental new drug application (sNDA) seeking approval of darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).1The sNDA is supported by data from the phase 3 ARANOTE trial (NCT04736199).
-
Nov 20, 2024 | 
oncnursingnews.com | Chris Ryan
The FDA granted fast track designation to ALE.P02, a anti–Claudin-1 (CLDN1) antibody-drug conjugate (ADC), as a potential treatment for patients with CLDN1-positive squamous solid tumors.1The first-in-class ADC features a tubulin inhibitor that is linked to an antibody designed to specifically target the CLDN1 epitope expressed on cancer cells.
-
Nov 15, 2024 | 
oncnursingnews.com | Chris Ryan
The FDA approved nilotinib (Danziten) without mealtime restrictions for adults with newly diagnosed Philadelphia chromosome (Ph)-positive chromic myeloid leukemia (CML) that is in chronic phase (CP-CML), as well as for adults with CP- and acute phase (AP)-CML that is resistant or intolerant to prior therapy, including imatinib (Gleevec).1 Nilotinib (Tasigna) was initially approved by the FDA in 2007 for the treatment of adult patients with Ph-positive CP- and AP-CML who were resistant or...
-
Nov 13, 2024 | 
oncnursingnews.com | Chris Ryan
A biologics license application (BLA) has been filed seeking the accelerated approval of datopotamab deruxtecan (Dato-DXd) for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) that has EGFR mutations and was previously treated with systemic therapies, including an EGFR-directed therapy.1 In a news release, AstraZeneca and Daiichi Sankyo also announced that they have voluntarily withdrawn the BLA for Dato-DXd in the treatment of patients with advanced or metastatic...
-
Nov 6, 2024 | 
oncnursingnews.com | Chris Ryan
The FDA extended the Prescription Drug User Fee Act (PDUFA) date for the biologics license application (BLA) seeking approval of zenocutuzumab (MCLA-128) to treat NRG1-positive non–small cell lung cancer (NSCLC) and pancreatic cancer.1 The regulatory agency previously granted priority review to the BLA in May 2024.2 However, additional time was required to review information submitted to the FDA in response to a chemistry manufacturing and controls request.1 No additional clinical data were...
